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Abstract Introduction: Emphysematous pyelonephritis (EPN) is a life-threatening
necrotising kidney infection, but there is no consensus on the best management.
Methods: We systematically reviewed previous articles published from 1980 to
2013 that included studies reporting on EPN, and applying the Cochrane guidelines,
we conducted a meta-analysis of the results.
Results: In all, 32 studies were included, with results for 628 patients (mean age
56.6 years, range 33.8–79.9). There were 462 women, outnumbering men by 3:1. Dia-
betes was present in 85% of the cases. Fevers and rigor (74.7%), pyuria (78.2%) and
pain (70.4%) were the most common symptoms. Shock was associated with 54.4%
of deaths while obstructive uropathy was associated with 15.1% of deaths. Com-
puted tomography was diagnostic in all the cases. Percutaneous drainage (PCD)
and medical management (MM) alone were associated with a signiﬁcantly lower
mortality rate than was emergency nephrectomy (EN), with an odds ratio (95% con-
ﬁdence interval) for PCD vs. EN of 3.13 (1.89–5.16; P< 0.001), for EN vs. MM of
2.84 (1.62–4.99; P = 0.001), and of 0.91 (0.53–1.56; P = 0.73, i.e., no difference) for
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MM, medical manage-
ment;
EN, nephrectomy;
OD, open drainage;
DM, diabetes mellitus;
OR, odds ratio
PCD vs. MM. Open drainage also had a signiﬁcantly lower mortality rate than EN,
with a ratio of 0.12 (0.02–0.91; P< 0.04).
Conclusion: The overall mortality rate was 18%; shock was associated with a
high mortality rate and therefore should be managed aggressively. PCD and MM
were associated with signiﬁcantly higher survival rates than EN, and therefore EN
should only be considered if the patient does not improve despite other treatments.
ª 2013 Production and hosting by Elsevier B.V. on behalf of Arab Association of
Urology.
Introduction
Emphysematous pyelonephritis (EPN) is a rare type of
necrotising infection, and as such is life-threatening if
not treated promptly. It is deﬁned as an acute and severe
infection of the renal parenchyma and peri-renal tissue,
which results in gas within the renal parenchyma, col-
lecting system or perinephric tissue [1–5]. Although it
was ﬁrst described in 1898, the term EPN was ﬁrst used
in 1962 [5]. It is more common in patients with diabetes
mellitus (DM) or patients who are immunocompro-
mised, with a female:male predominance of 4:1 and a
mean (range) age of 57 (24–83) years [5,6].
Although it is a life-threatening illness with a mortal-
ity rate of up to 50% there is no consensus on the best
management of these patients [5]. The main focus of
treatment is an emergency nephrectomy (EN), percuta-
neous drainage (PCD), or medical management (MM),
with or with no stenting of the urinary tract. Some re-
ports recommend that EN should be the mainstay of
treatment and not be delayed [2,3], but others recom-
mended a more conservative approach with PCD [6–
8], and a purely conservative approach with MM alone
has also been advocated [9–11], which further increases
the management conundrum.
To aid in the decision, a few reports have been pub-
lished with mortality rates stratiﬁed by risk variables,
delineating which patients need more aggressive man-
agement than others [10,12–16]. However, these were
not only based on relatively few patients, but between
the studies they also had varying results for the same
risk variable. Furthermore, other studies attempted to
delineate the management based on the CT ﬁndings,
but these too were also based on few patients and were
not based on robust classiﬁcations [3,7,17–19].
Nonetheless, because there is no substantive evidence,
these reports remain the only available guide to aid cli-
nicians in managing EPN. Thus the aim of this study
was to systematically review previous reports and, using
a meta-analysis, to determine the mortality rate of each
treatment from the available series. Furthermore, we
aimed to stratify the prognostic factors across the pub-
lished studies to determine the speciﬁc factors for EPN
and their association with death, and to describe the
clinical and laboratory presentation of patients with
EPN.
Methods
Search strategy and study selection
The systematic review was conducted using the Cochra-
ne review guidelines, and cross checked with the PRIS-
MA guidelines. The search strategy was devised to ﬁnd
relevant studies from Medline (1980 to February
2013), EMBASE (1980 to February 2013), the Cochrane
Central Register of Controlled Trials (in The Cochrane
Library, Issue 1 to 2013), CINAHL (1980 to February
2013), www.clinicaltrials.gov, Google Scholar and indi-
vidual urological journals. The search was made on 2
February 2013.
The search terms used included: ‘emphysematous
pyelonephritis’, ‘emphysematous nephritis’, ‘emphyse-
matous pyelitis’, ‘necrotising renal infection’, and ‘gas-
eous renal infection’. Papers in languages other than
English were included if the data were extractable, and
the references of papers were evaluated for potential
inclusion.
Three reviewers independently identiﬁed all studies
that met the inclusion criteria for evaluation. Three
reviewers independently extracted the data for inclusion.
One reviewer correlated all data extraction. Disagree-
ment between the reviewers was resolved by consensus.
A qualiﬁed statistician reviewed all the data and con-
ducted the statistical analysis.
Data extraction and analysis
Studies reporting on four or more cases of EPN were in-
cluded. The main aim was to assess the mortality rate
associated with EPN, depending on the various treat-
ments offered. The three main treatments reviewed were
EN, PCD and conservative MM. Further treatments
were also compared where reported. The secondary out-
come was to assess the more common risk factors asso-
ciated with death, and the most common presenting
symptoms, diagnostic investigations, and most common
causative organisms. Where available, patients with risk
factors for death were compared to those with no risk
factors. Furthermore, the risk of death was assessed
based on the different types of classiﬁcation of EPN.
The Wan classiﬁcation divides EPN into type I (severe)
and type II (mild) [4], with type I deﬁned as parenchy-
mal destruction with either total absence of ﬂuid content
on CT, or the presence of a streaky gas pattern regard-
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less of the absence or presence of bubbly or loculated
gas [4]. Type II was deﬁned as the presence of renal or
perirenal ﬂuid in association with a bubbly or loculated
gas pattern, or as gas in the collecting system, with acute
bacterial nephritis or renal or perirenal ﬂuid containing
an abscess [4]. The Huang classiﬁcation is more detailed,
whereby class I EPN is deﬁned as gas in the collecting
system only, class II as gas in the renal parenchyma with
no extension to the extrarenal space, class IIIa as exten-
sion of gas or abscess to the perinephric space, class IIIb
as extension of gas or abscess to the pararenal space,
and class IV as bilateral EPN or EPN in a solitary kid-
ney [18]. We compare the two classiﬁcations. As Huang
classes I and II are considered mild, and classes III and
IV severe, we grouped them in this way, as adopted by a
few of the studies [12,16,20,21].
The following variables were extracted from each
study: patient demographics, length of hospital stay,
presenting symptoms, diagnostic investigations, culture
results, laboratory ﬁndings, treatment, and mortality
rate. Only similar results that could be pooled from
the included studies were meta-analysed.
For continuous data, a Mantel–Haenszel chi-square
test was used and expressed as the mean difference with
95% CI, and for dichotomous data an inverse variance
was used and expressed as the odds ratio (OR) with 95%
CI. In both cases P< 0.05 was considered to indicate
signiﬁcance.
Heterogeneity was analysed using a chi-squared test
on (N1) degrees of freedom, with an a of 0.05 used
to denote statistical signiﬁcance, and with the I2 test
[22], where I2 values of 25%, 50% and 75% correspond
to low, medium and high levels of heterogeneity. A
ﬁxed-effect model was used unless there was statistically
signiﬁcant high heterogeneity (where I2 > 75% was
considered as signiﬁcantly high heterogeneity) between
studies. A random-effects model was used if there was
heterogeneity.
The methodological quality of the studies included in
the meta-analysis was assessed as described in the Coch-
rane handbook [22,23], and the quality assessment was
plotted.
Results
The search identiﬁed 504 studies, of which 420 were ex-
cluded due to irrelevance based on titles, and 36 ex-
cluded due to irrelevance based on the abstracts
(Fig. 1). Full reports were evaluated in 48 studies, of
which 32 were included in the systematic review [1–
3,6–8,10–21,24–37]. Most of the studies were published
within the last 10 years, reﬂecting the increased aware-
ness of EPN and the associated controversy. After read-
ing the full reports, 16 studies were excluded for various
reasons [4,5,9,38–50]; eight were case reports
Table 1 The studies included and patient demographics.
Ref. Period M:F Mean (range) Age, years R:L:bilat:graft
[1] NM 8:3 56.3 NM
[2] 1980–95 5:15 55 7:12:1
[3] 1991–99 1:20 61 (11.1) 9:11:1
[6] 2000–2010 8:25 51 (10.9) 12:15:3
[7] 1984–95 7:18 60.6 13:12
[8] 1993–2004 3:23 58.7 (12.7) 13:11:2
[10] 1995–2009 11:12 62.8 (17.1) 8:13:1:1
[11] 2008–2011 4:4 49.63 (8.99) ?:?:4
[12] 2004–2008 6:33 57 (7.2) 6:28:4
[13] 2005–2010 1:17 52.4 NM
[14] 1986–93 5:33 54.7 ?:?:2
[15] 2001–2007 3:13 61.2 (11.5) 6:9:1
[16] 2001–2007 3:16 43.6 (8.9) 3:11:5
[17] 2000–2009 7:17 61.8 11:11:2
[18] 1989–97 7:41 60 12:32:4
[19] 1986–96 7:21 61.6 13:14:1
[20] 2001–2007 22:19 55 (7.3) 19:13:8
[21] 2005–2009 10:18 NM NM
[24] 1996–2004 1:6 44.5 2:5
[25] 1980–85 3:10 53 7:5:1
[26] NM 2:3 53 (4.77) NM
[27] 2006–2010 3:10 NM 5:4:4
[28] 1992–2002 1:9 61.2 NM
[29] 1987–2009 10:20 58.5 9:20:1
[30] 1987–2004 6:15 54.6 6:14:1
[31] NM 2:3 51 (16.39) 3:2
[32] 2003–2005 7:13 54.4 (20.6) 10:06:2
[33] NM 4:4 NM NM
[34] 1986–91 2:2 62 (11.34) 2:2
[35] NM 1:3 51.25 (10.21) 3:1
[36] 1998–99 1:5 63.8 (13.63) 3:2
[37] 1986–2004 5:12 52 7:8:2
NM, not mentioned.
Table 2 Symptoms and the organisms cultured.
Symptoms n/total n (%)
Pyuria 161/206 (78.2)
Fevers and rigors 316/423 (74.7)
Pain 269/382 (70.4)
Haematuria 40/136 (29.4)
Shock 104/423 (24.6)
Obstructive uropathy 197/572 (34.4)
Organism cultured
Blood culture
Escherichia coli 186/351 (53)
Klebsiella pneumoniae 27/157 (17.2)
Proteus sp. 2/39 (5.1)
Urine culture
Escherichia coli 347/552 (62.9)
Klebsiella pneumoniae 81/416 (19.5)
Pseudomonas sp. 6/102 (5.9)
Proteus 9/139 (6.5)
Pus culture
Escherichia coli 115/208 (55.3)
Klebsiella pneumoniae 26/142 (18.3)
Negative cultures
Blood 99/339 (29.2)
Urine 68/307 (22.2)
Pus 8/87 (9.2)
108 Aboumarzouk et al.
[9,38,40,43,44,46,47,49], while ﬁve others were excluded
as they were reporting on emphysematous cystitis
[41,42,45,48,50], and two were excluded as they were
systematic reviews [5,39]. The ﬁnal excluded study,
Wan et al. [4] was excluded, as they reported an updated
version of their data, which were included in this review
[14].
Characteristics of the included studies
Although the search was conducted between 1980 and
2013, all except for seven of the 32 reports were published
after 2000, with over half (18) published after 2007. The
reporting study period was 1980–2011. All the studies re-
ported patient age except for three [1–3,6–8,10–20,24–
26,28–32,34–37], and all studies reported on the diabetic
status of the patients, while all but six reported on the
mortality rate associated with DM [1,3,8,10,11,13–
20,24–28,30–37]. All studies except eight reported on
an aspect of the presenting symptom [1–3,6–8,10,11,13–
19,21,24–30,32,34–37]. While 21 of the studies reported
on whether or not the patients were in shock [2,6,8,10–
13,16–18,20,21,24–26,29–34], only 14 reported deaths
associated with shock [2,6,11,16,18,20,21,24, 25,29,
30,32–34]. The status of renal tract obstruction was re-
ported by 28 of the studies [1–3,6–8,11,12,14–
21,24,25,27,29–37], but only 11 reported on deaths asso-
ciated with obstruction [1,8,11,15,18,25,31,33–36]. All
studies but eight reported on laterality [2,3,6–
8,10,12,15–20,24,25,27,29–32,34–37].
Twenty-three studies reported one or more aspects of
the laboratory ﬁndings [2,6,8,10–14,16,18,20,21,24,
26,28–37], all reported on the diagnostic method used
and the most common causative organism, and all re-
Literature Search (No. = 504)
Potential Articles for evaluation 
of Abstract (No. = 84) 
Articles excluded after screening of 
the Title (No. = 420) 
Articles excluded after 
screening Abstracts (No. = 36) Potential Articles for evaluation of 
Full Manuscript (No. = 48)
Articles excluded after 
screening Full Manuscripts 
(No. = 16) 
Included Articles (No. = 32)
Fig. 1 The ﬂowchart of the articles selected.
Table 3 Treatments and associated mortality rates, with the risk comparisons of treatments.
Treatment No. of deaths/total (%) Comparison, OR (95% CI) P
EN 42/126 (33.3)
PCD 39/283 (13.8)
MM 25/167 (15)
OD 1/18 (6)
PCD followed by DN 5/47 (10.6)
MM followed by DN 1/4
EN vs. PCD 3.13 (1.89–5.16) <0.001
PCD vs. MM 0.91 (0.53–1.56) 0.73
EN vs. MM 2.84 (1.62–4.99) <0.001
PCD+DN vs. EN 0.24 (0.09–0.65) <0.005
PCD+DN vs. PCD 0.74 (0.28–2.00) 0.56
PCD+DN vs. MM 0.68 (0.24–1.88) <0.45
OD vs. EN 0.12 (0.02–0.91) <0.04
OD vs. PCD 0.37 (0.05–2.84) <0.34
OD vs. MM 0.33 (0.04, 2.62) <0.3
OD vs. PCD+DN 0.49 (0.05–4.55) <0.53
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ported on the treatment used and accompanying mortal-
ity rate. Eight studies classiﬁed EPN according to the
Wan classiﬁcation [3,7,13–15,18,27,28], whilst 11 classi-
ﬁed EPN according to the Huang classiﬁcation [6,10–
13,16,18,20,21,31,32], but two were not included in the
pooled analysis as they had not reported which patients
died according to which classiﬁcation they were in [6,13].
Meta-analysis results
In all there were 628 patients (mean age 56.6 years,
range 33.8–79.9) (Table 1), comprising 166 men and
462 women, and 85.2% (535/628) of the patients had
DM. Of the studies that reported laterality, 37.7%
(189/502) of patients had right-sided, vs. 52% (261/
502) left-sided, EPN, with 10.2% (51/502) being bilater-
ally involved and 0.2% (1/502) being in a transplanted
kidney.
Table 2 shows the incidence of symptoms in the pa-
tients, with pyuria being the most prevalent, followed
by fevers and rigors, pain, haematuria, shock, and
obstructive uropathy. Leucocytosis was present in
72.8% (214/294), thrombocytopenia in 40.3% (83/
206), and deranged renal function (acute renal failure)
in 45.2% (174/385). The organisms that were grown in
culture are also listed in Table 2.
CT was accurate for detecting EPN in all 628 cases,
whilst the accuracy rate for plain radiography was
53.2% (101/190) and for ultrasonography was 67.9%
(188/277).
In all there were 215 deaths (18%) and Table 3 shows
the mortality rates categorised according to the various
treatments reported. For comparing the treatments, the
OR (95% CI) are also shown in Table 3, and the details
of individual studies as Forest plots in Fig. 2, where
studies that did not report evaluable data for the plot
are not listed.
A subgroup analysis of the effect of the presence of
risk factors on mortality is shown in Table 4. The death
rate was 19.5% in those with DM, vs. 20.7% in those
without (P= 0.82). More patients who presented in
shock (54.4%) died than did those with no shock
(6.9%) (P< 0.001). Fewer patients with obstructive
uropathy (15.1%) died than did those with no obstruc-
tion (30.9%) (P= 0.04) (Table 4).
A subgroup analysis based on the CT classiﬁcation
showed that 189 patients were classiﬁed using the Wan
system, with 69 of type I and 120 of type 2, of which
31.9% (22) died in the ﬁrst group (severe EPN) vs.
13.3% (16) in the second (mild EPN) group (Table 4).
The Huang classiﬁcation was used for 231 patients, with
119 in classes I and II, and 112 in classes III and IV, of
whom 5% (six) died in the ﬁrst group (mild EPN) and
29.5% (33) died in the second (severe EPN) group (Ta-
ble 4). Comparing the severe EPN groups of each classi-
ﬁcation showed no difference between the groups
(Table 4).
Methodological quality assessment
All the included studies were case series, with no ran-
domisation or control groups, and all reported on their
centre’s experience in managing patients with EPN.
Based on the reviewing authors, the judgement of the
hierarchy of evidence for each study was that the evi-
dence was of low quality. However, collectively, the
meta-analysis strengthens the level of evidence, despite
being a meta-analysis of case series. It is difﬁcult to con-
duct a study of emergency procedures, let alone rando-
mise or even compare either of the methods to a
control group. Hence it is unlikely that these types of
studies will be conducted, and evidence-based guidance
must be obtained from systematic reviews and meta-
analysis of cases series such as these.
Discussion
The results of the meta-analysis showed that EPN has a
3:1 female to male ratio, and occurs predominantly in
patients with DM, with an incidence of 85%. The simple
explanation is that this gives a combination of high tis-
sue glucose concentrations, impaired tissue perfusion,
and the presence of gas-producing organisms, the ideal
environment for developing EPN [17]. The high tissue
glucose level acts as a substrate for the micro-organisms
to produce hydrogen and carbon dioxide by fermenta-
Table 4 Risk factors and CT classiﬁcations with associated mortality rates.
Risk factors Deaths/total reported P OR (95% CI)
DM vs. no DM 78/401 vs. 12/58 0.82 0.93 (0.47–1.83)
Shock vs. no shock 37/68 vs. 15/215 <0.001 15.91 (7.83–32.34)
Obstruction vs. no obstruction 8/53 vs. 30/97 0.04 0.4 (0.17–0.94)
Classiﬁcations
Wan class I vs. II 22/69 vs. 16/120 0.003 3.04 (1.47–6.32)
Huang Class I + II 6/119 vs. 33/112 <0.001 0.13 (0.05–0.32)
vs. III + IV
Wan Class 1 vs. 22/69 vs. 33/112 0.73 0.02 (– 0.11–0.16)
Huang Class III + IV
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tion [17]. In patients with no DM, urinary albumin is
thought to substitute for glucose [17], but glucose is a
more favourable substrate for the gas-producing organ-
isms, and thus EPN is more prevalent in the patient with
DM.
The most common symptoms are fever and rigors,
pyuria, and pain, with a high incidence of leucocytosis.
The most common causative organism in laboratory
cultures was Escherichia coli, followed by Klebsiella
pneumoniae, then Proteus sp. CT was the diagnostic test
of choice, with a 100% detection rate. Therefore, once
EPN is suspected, CT must not be delayed to conﬁrm
the diagnosis.
We identiﬁed that the mortality rate associated with
EPN was not as high as previously reported, and the
present meta-analysis of previous reports showed a com-
bined mortality rate of 18%. A subgroup analysis
showed that although EPN is signiﬁcantly more com-
mon in patients with DM, there was no difference in
the mortality rate between patients with and without
DM (Table 4). We hypothesise that this is mainly due
to the control of DM, initiated in the affected patients
by all reporting authors. By managing the DM medi-
cally, the risk of death from EPN becomes similar to
that of patients without DM. However, if shock was a
presenting symptom then the risk of death was signiﬁ-
cantly higher than if it was not; over 54% of patients
who had shock ﬁnally died from EPN (Table 4).
Interestingly, despite it being obvious that renal
obstruction would have a worse prognosis, we found
that the mortality rate was signiﬁcantly higher in pa-
tients with no obstructive uropathy (Table 4). Again,
we postulate that this is probably because clinicians
aggressively managed the obstruction, and once re-
lieved, the source of sepsis dissipated, allowing a better
outcome.
Fig. 2 Mortality rate comparisons: a, DM vs. no DM; b, Shock vs. no shock; c, Obstructive uropathy vs. no obstruction; d, EN vs.
PCD; e, PCD vs. MM; and f, EN vs. MM.
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There are many different treatment options, with EN,
PCD and MM being the major methods. All reports
mentioned that all the patients were managed medically,
i.e., with antibiotics, diabetic control, and ﬂuids at pre-
sentation, before initiating the ﬁnal treatment option.
Nonetheless, we found that 20% of the patients had
EN, 45% had PCD, 26.6% had MM, 2.8% had OD,
4.8% had PCD and DN, and 0.6% had MM and DN.
There were an additional 17 patients in the PCD+DN
group who had a complete resolution of their EPN, but
had a DN nonetheless, with no clear reason given.
Comparing the top three treatments, both PCD and
MM were associated with signiﬁcantly lower mortality
rates than was EN. Furthermore, the results were similar
when comparing these groups of patients to those who
also had OD and PCD+DN. We did not compare
the groups to those who had MM+DN as there were
only four patients in the last group.
Comparing the severe to mild classes, there were sig-
niﬁcantly more patients who died in the severe class than
the mild, for both the Wan and Huang classiﬁcation
(Table 4). Furthermore, comparing the severe classes
of each classiﬁcation, there was no signiﬁcant difference
in the death rate, which suggests that both classiﬁcations
are reliable (Table 4).
Implications for practice
Based on these results, it is our view that the initial med-
ical therapy, mainly with antibiotics and ﬂuids where
needed, and adequate diabetic control, is optimal, and
once the diagnosis of EPN is established the clinician
should consider either PCD of the abscess, or use com-
plete MM. If the patient is showing signs of shock or
end-organ failure that is not responding to MM, then
we recommend consultation with an intensive-care spe-
cialist for early supportive care and admission to a
high-dependency unit, as the evidence suggests these pa-
tients have the highest mortality rates. From the avail-
able evidence, we also recommend that if PCD or MM
Fig. 2 (continued)
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is not improving the patient’s condition, then OD must
be considered before considering a nephrectomy. To this
end, based on the evidence, we constructed a ﬂow chart
to aid clinicians in managing EPN (Fig. 3).
Furthermore, as there are two schemes for classifying
EPN that have been widely adopted, based on imaging
ﬁndings, we recommend classifying EPN into either
one of these schemes, as we found no signiﬁcant differ-
ence in the ﬁnal outcome for either. Although the pa-
tient’s condition should direct the management,
classifying into mild or severe EPN would also be an
aid to management.
The strengths and limitations of the review
The main limitation of this review is the type of
studies included in the meta-analysis. All the studies
were case series reporting their centre’s experience
of managing EPN. However, for such a rare disease,
in emergency circumstances, it is difﬁcult to include
patients into well-formulated trials, and we must
therefore rely on this type of report for evidence.
Collating them and using meta-analyses of the results
strengthens the level of evidence provided. Further-
more, the studies were reported from various centres
worldwide, which adds some variability to the data,
thus allowing for the generalisation of the end
results.
Nonetheless, this review was impartial and conducted
systematically and methodically in keeping with the
Cochrane standards. This report represents the evidence
available, reporting on the incidence, risk factors associ-
ated with, and investigations, treatment and mortality
rates of EPN.
Fig. 2 (continued)
Emphysematous pyelonephritis: Time for a management plan 113
In conclusion, the results of this systematic review
and meta-analysis show that EPN has an overall mortal-
ity rate of about 18%. PCD and MM are associated
with signiﬁcantly higher survival rates than EN, and
therefore EN should only be considered if the patients
persistently do not improve despite other treatments.
Survival is improved if diabetic management is initiated
immediately, and aggressive treatments of sepsis are also
started as soon as possible.
The best diagnostic method is CT, which also aids in
classifying EPN. Severe EPN is associated with a high
mortality rate, and therefore more aggressive treatment
is recommended.
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